Cipla Limited

Cipla Limited

Cipla Limited has informed the Exchange about the schedule of Earnings Conference Call to be held on 27th October, 2026, where the leadership team will discuss financial performance and take questions. The company will release Q2FY27 unaudited Financial Results on the same day.

Cipla Limited

Cipla Limited has informed the Exchange regarding the allotment of 12,168 shares under the Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021.

Cipla Limited

Cipla Limited has informed the Exchange about change in Senior Management Personnel. Mr Venkata Sai Mungara, Global Head Supply Chain, has transitioned to the role of Chief of Manufacturing and Supply Chain Operations of Cipla USA Inc. with effect from 1st October, 2026. He will cease to be a Senior Management Personnel of the Company.

Cipla Limited

Cipla Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI registered ESG Rating Provider.

Cipla Limited

Cipla Limited has announced an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to Keytruda (Pembrolizumab) in the US.

Cipla Limited

Cipla Limited has issued a notice to shareholders and creditors regarding the merger of Inzpera Healthsciences Limited with the company, as per the order of the National Company Law Tribunal (NCLT) dated 18th August, 2026.

Cipla Limited

Cipla Limited has informed the Exchange about Newspaper Publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares.

Cipla Limited

Cipla Limited has entered into an exclusive licensing agreement with SBP Group for the development and commercialization of Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific antibody-drug conjugate, in India, South Africa, and other emerging markets.

Cipla Limited

Cipla Limited has informed the Exchange about the outcome of the USFDA inspection at its InvaGen manufacturing facility in Central Islip, Long Island, NY, USA, which has been classified as Voluntary Action Indicated (VAI).

Cipla Limited

Cipla Limited has informed the Exchange about Other Restructuring, where Aspergen Limited, India, a 60:40 joint venture between the Company and Kemwell Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary of the Company, from Cipla (EU) Limited (holding 60% stake), a wholly owned subsidiary of the Company, and Kemwell Biopharma UK Limited (holding 40% stake). Consequently, Aspergen Inc., USA has become a wholly owned subsidiary of Aspergen Limited, India. There is no change in the Company's economic interest in Aspergen Inc., USA, pursuant to the aforesaid restructuring.

Cipla Limited

Cipla Limited has informed the Exchange about the schedule of Analyst / Institutional Investor Meetings with the Company.

Cipla Limited

Cipla Limited has informed the Exchange regarding the allotment of 5281 shares under the Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. The issued, subscribed, and paid-up share capital of the Company stands increased to INR 161,57,16,894 comprising of 80,78,58,447 equity shares of face value INR 2 each.

Cipla Limited

Cipla Limited has informed the Exchange about a USFDA inspection at its manufacturing facility in Pithampur, India, where seven inspectional observations were noted in Form 483. The company will work with the USFDA to address these observations comprehensively within the stipulated time.

Cipla Limited

Cipla Limited has informed the Exchange about receipt of order from Hon'ble NCLT, Mumbai Bench, allowing the Scheme of Amalgamation of Inzpera Healthsciences Limited with Cipla Limited.

Cipla Limited

Cipla Limited has been assigned ESG ratings by SES ESG Research Private Limited and NSE Sustainability Ratings & Analytics Limited. SES assigned a rating of 69.9 (Grade B) for FY 2025-26, a slight improvement from 69.3 (Grade B) for FY 2024-25. NSE assigned a rating of 67 (Aspiring) for FY 2025-26, a decline from 69 (Aspiring) for FY 2024-25, potentially due to a product recall by Cipla USA Inc.

Cipla Limited

Cipla Limited has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection at its InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA.

Cipla Limited

Cipla Limited has informed the Exchange regarding allotment of 7850 securities pursuant to ESOP/ESPS at its meeting held on July 31, 2026. The issued, subscribed and paid-up share capital of the Company stands increased to INR 1,61,57,06,332 comprising of 80,78,53,166 equity shares of face value INR 2 each.

Cipla Limited

Cipla Limited has received US FDA approval for its Generic Advair Diskus, a dry powder inhaler for asthma and COPD treatment, marking a significant milestone in the company's expansion of complex respiratory capabilities in the US.

Cipla Limited

Cipla Limited has released the transcript of its Q1 FY27 earnings conference call, which was held on July 23, 2026. The company reported its highest ever Q1 revenue with revenues of INR7,100 crores, driven by strong performance across key therapies and a diversified business.

Cipla Limited

Cipla Limited has informed the Exchange about the unaudited financial results for the quarter ended 30th June, 2026. The results have been published in Business Standard (English) and Sakal (Marathi).